Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea

PHASE3TerminatedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

November 30, 2015

Conditions
Sickle Cell Anemia
Interventions
DRUG

Hydroxyurea

Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Boston Children's Hospital

OTHER

collaborator

University of Texas Southwestern Medical Center

OTHER

collaborator

Children's Healthcare of Atlanta

OTHER

collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

The Hospital for Sick Children

OTHER

collaborator

Children's National Research Institute

OTHER

collaborator

Columbia University

OTHER

collaborator

St. Jude Children's Research Hospital

OTHER

collaborator

University Hospitals Cleveland Medical Center

OTHER

collaborator

University of South Alabama

OTHER

collaborator

Medical University of South Carolina

OTHER

collaborator

University of Alabama at Birmingham

OTHER

collaborator

University of Miami

OTHER

collaborator

University of Mississippi Medical Center

OTHER

collaborator

Wayne State University

OTHER

collaborator

Children's Hospital of The King's Daughters

OTHER

collaborator

Nemours Children's Clinic

OTHER

collaborator

Duke University

OTHER

collaborator

East Carolina University

OTHER

collaborator

Children's Hospitals and Clinics of Minnesota

OTHER

collaborator

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

collaborator

Baylor College of Medicine

OTHER

collaborator

State University of New York - Downstate Medical Center

OTHER

collaborator

Steven and Alexandra Cohen Children's Medical Center

INDIV

lead

Children's Hospital Medical Center, Cincinnati

OTHER